Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
"AT RISK PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
SPECIAL AUTHORIZATION (step therapy approval process)
FIRST-LINE DRUG PRODUCT(S): WARFARIN
For at-risk patients (CHADS2 score of greater than or equal to 1) with non-valvular atrial fibrillation (AF) for the prevention of stroke and systemic embolism AND in whom one of the following is also present: - Inadequate anticoagulation (at least 35% of INR testing results outside the desired range) following a reasonable trial of warfarin (minimum two months of therapy); OR - Anticoagulation with warfarin is contraindicated as per the product monograph or not possible due to inability to regularly monitor via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, or at home).
Note: Some or all direct oral anticoagulants may have contraindications to use or precautions with use, for example: related to prosthetic heart valve disease, rheumatic valvular heart disease, renal function, or age. Refer to the product monograph for additional information.
Special Authorization may be granted for 24 months.
Note: If a claim for the Step therapy drug product is rejected, pharmacists can use their professional judgment to determine the appropriateness of using the intervention code(s) noted below to re-submit a claim. The pharmacist is responsible to document on the patient's record the rationale for using the second-line therapy drug. UP - First-line therapy ineffective UQ - First-line therapy not tolerated
VENOUS THROMBOEMBOLIC EVENTS
SPECIAL AUTHORIZATION
For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE).
The recommended dose of edoxaban for patients initiating DVT or PE treatment is 60 mg once daily following initial use of a parenteral anticoagulant for 5-10 days. A reduced dose of 30 mg once daily is recommended for patients with one or more of the following clinical factors: - moderate renal impairment (creatinine clearance (CrCL) 30-50 mL/min) - low body weight <= 60 kg (132 lbs) - concomitant use of p-glycoprotein inhibitors except amiodarone and verapamil.
Drug plan coverage for edoxaban is an alternative to heparin/warfarin for up to 6 months. When used for greater than 6 months, edoxaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy greater than 6 months should be considered for initiation on heparin/warfarin.
Special authorization may be granted for up to 6 months."
All requests for edoxaban must be completed using the Dabigatran/Edoxaban Special Authorization Request Form (ABC 60019).
CDR - List with clinical criteria and/or conditions
Indication
NONVALVULAR ATRIAL FIBRILLATION, PREVENTION OF STROKE & SYSTEMIC EMBOLISM
Reviewing Body
Common Drug Review
Submission Completion Date
2016/09/23
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2019/03/01
CDR Recommendation
Review Status
Step Therapy/Special Authorization
SERVIER CANADA INC. (SEV)
Telephone:(450) 978-9700
Toll-Free:(800) 663-0839
To return to the printable Drug Benefit List and related publications,
click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.